Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.45 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.45 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.45 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978071 | 0.94 | CNR1 (0.53) | POLBCNR1CNR2PPARDPLAAT3 | |
| SCHEMBL9978065 | 0.87 | CNR1 (0.50) | POLBCNR1CNR2PPARDGLA | |
| SCHEMBL9978092 | 0.86 | CNR1 (0.55) | POLBCNR1CNR2PPARD | |
| SCHEMBL9978149 | 0.85 | CNR1 (0.53) | POLBCNR1CNR2PPARDNPC1 | |
| SCHEMBL9978045 | 0.85 | CNR1 (0.48) | POLBCNR1CNR2PPARD | |
| SCHEMBL9978172 | 0.84 | POLB (0.56) | POLBCNR1CNR2PLAAT3PLAAT5 | |
| SCHEMBL9978037 | 0.83 | CNR1 (0.51) | POLBCNR1CNR2PPARDNPC1 | |
| SCHEMBL9937741 | 0.82 | CNR1 (0.50) | CNR1CNR2PPARDNPC1RAB9A | |
| SCHEMBL9978072 | 0.82 | CNR1 (0.49) | POLBCNR1CNR2PPARDTRPM8 | |
| SCHEMBL9978007 | 0.80 | CNR1 (0.52) | POLBCNR1CNR2PPARDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9925251-B2 | Treatments for Mycobacterium tuberculosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925251-B2 | Treatments for Mycobacterium tuberculosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-03-27 | — | — | US | disclosed |
| US-20140243255-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2014-08-28 | — | — | US | disclosed |
| US-20140243255-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2014-08-28 | — | — | US | disclosed |
| WO-2013059622-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012079164-A1 | ACTIVATORS OF CYLINDRICAL PROTEASES | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012079164-A1 | ACTIVATORS OF CYLINDRICAL PROTEASES | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243255-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | CLPP, LONP1, CLPX | POLB 927/4885CNR1 4284/4885CNR2 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.